Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) hit a new 52-week high on Monday after StockNews.com upgraded the stock from a buy rating to a strong-buy rating. The company traded as high as $9.10 and last traded at $9.06, with a volume of 469675 shares changing hands. The stock had previously closed at $8.73.
A number of other equities research analysts also recently weighed in on AMRX. Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday. Barclays upped their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial upped their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $10.00.
Read Our Latest Stock Analysis on Amneal Pharmaceuticals
Institutional Trading of Amneal Pharmaceuticals
Amneal Pharmaceuticals Trading Up 5.4 %
The company has a market cap of $2.85 billion, a price-to-earnings ratio of -13.53 and a beta of 1.17. The business has a fifty day moving average price of $8.53 and a two-hundred day moving average price of $7.56.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $701.78 million for the quarter, compared to the consensus estimate of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current year.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
See Also
- Five stocks we like better than Amneal Pharmaceuticals
- How to Effectively Use the MarketBeat Ratings Screener
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Which Wall Street Analysts are the Most Accurate?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Where to Find Earnings Call Transcripts
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.